News Column

Takeda and Zinfandel Pharmaceuticals to Present Data at Upcoming Alzheimer's Association International Conference® Highlighting Innovative Approaches...

July 23, 2014



Takeda and Zinfandel Pharmaceuticals to Present Data at Upcoming Alzheimer's Association International Conference® Highlighting Innovative Approaches to Alzheimer's Disease Research and Development

By a News Reporter-Staff News Editor at Biotech Week -- -Takeda Pharmaceutical Company Limited ("Takeda") and its partner, Zinfandel Pharmaceuticals, Inc. ("Zinfandel"), will present data during multiple poster and oral sessions at the upcoming Alzheimer's Association International Conference(®) 2014 (AAIC(®)), taking place in Copenhagen, Denmark from July 12-17, 2014 (see also Takeda Pharmaceutical Company Limited).

"Studies show that individuals with mild cognitive impairment--a slight, although noticeable and measurable decline in cognitive abilities--are at an increased risk of developing Alzheimer's disease or another dementia. An option to be able to predict an individual's risk for developing this disease would be welcomed by the medical community," said Stephen Brannan, M.D., Central Nervous System Development Therapeutic Area Head, Takeda. "Therefore, a special focus for Takeda at this conference will be presenting updates on the TOMMORROW Trial--a trial that challenges the status quo and aims to accelerate the progress toward identifying effective therapeutic agents for Alzheimer's disease."

Keywords for this news article include: Takeda Pharmaceutical Company Limited, Tauopathies, Alzheimer Disease, Neurodegenerative Diseases, Central Nervous System Diseases.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters